Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways
Authors:
- K. McEversKMK. McEvers
- M. ElrefaeiMEM. Elrefaei
- P. NorrisPNP. Norris
- S. DeeksSDS. Deeks
- J. MartinJMJ. Martin
- Y. LuYLY. Lu
- H. CaoHCH. Cao
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- A Sound Rationale Needed for Phase III HIV-1 Vaccine TrialsScience, 2004
- T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral TherapyThe Journal of Infectious Diseases, 2003
- Disappointing Data Scuttle Plans for Large-Scale AIDS Vaccine TrialScience, 2002
- Delivery of Exogenous Protein Antigens to Major Histocompatibility Complex Class I Pathway in CytosolThe Journal of Infectious Diseases, 2002
- Identification of the cellular receptor for anthrax toxinNature, 2001
- Multiple Effector Functions Mediated by Human Immunodeficiency Virus-Specific CD4+T-Cell ClonesJournal of Virology, 2001
- Robust HIV Type 2 Cellular Immune Response Measured by a Modified Anthrax Toxin-Based Enzyme-Linked Immunospot AssayAIDS Research and Human Retroviruses, 2001
- Cellular immune responses to HIVNature, 2001
- Protective antigen‐binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino‐ or carboxy‐terminusMolecular Microbiology, 1995
- Purification of the Third Factor of Anthrax ToxinJournal of General Microbiology, 1962